Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer
Cancer Cell  (IF31.743),  Pub Date : 2021-11-11, DOI: 10.1016/j.ccell.2021.11.001
Siang-Boon Koh, Leif W. Ellisen

Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.